[Ventricular arrhythmias : What has been confirmed in therapy?]
D Duncker1, J Bauersachs1, C Veltmann2
1Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Der Internist
|October 27, 2017
Summary
Ventricular arrhythmias range from mild to life-threatening, requiring accurate diagnosis via ECG and monitoring. Treatment includes medication, ablation, and defibrillators to manage risks like sudden cardiac death.
Area of Science:
- Cardiology
- Electrophysiology
- Internal Medicine
Background:
- Ventricular arrhythmias encompass a spectrum from benign premature contractions to life-threatening ventricular tachycardia and fibrillation.
- Sudden cardiac death is a significant risk associated with ventricular arrhythmias.
- Accurate diagnosis, particularly of wide complex tachycardias, is crucial for effective management.
Purpose of the Study:
- To provide a comprehensive overview of ventricular arrhythmia diagnosis and management.
- To detail the diagnostic work-up for underlying cardiomyopathies.
- To present current therapeutic options and indications for defibrillators.
Main Methods:
- Diagnosis utilizes 12-lead electrocardiogram, 24-hour Holter monitoring, and loop recorders.
- Differentiating ventricular tachycardia from supraventricular tachycardia with aberrant conduction is a key diagnostic challenge.
- Risk stratification for sudden cardiac death follows documentation of ventricular arrhythmias.
Main Results:
- Diagnostic work-up includes assessment for structural or electrical cardiomyopathies.
- Therapeutic strategies encompass pharmacological treatments, catheter ablation, and implantable devices.
- Indications for implantable and wearable defibrillators are presented.
Conclusions:
- Effective management of ventricular arrhythmias requires accurate diagnosis and risk stratification.
- A range of medical and interventional therapies are available.
- Defibrillator implantation is a critical option for high-risk patients.
Keywords:
Catheter ablationDeath, sudden, cardiacExtrasystole, ventricularTachycardia, ventricularVentricular fibrillationMore Related Videos
12:15Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
Published on: February 8, 2022
3.0K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
11.1K
Related Concept Videos
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
643
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
643
01:25Dysrhythmias VI: Management of Dysrhythmias
509
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
509
01:22Heart Failure VI: Adjunct Therapies
417
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
417
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.6K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.6K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.3K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.3K